新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 葛兰素史克 » Adimab宣布将与葛兰素史克公司合作开发双特异性抗体

Adimab宣布将与葛兰素史克公司合作开发双特异性抗体

来源:生物谷 2015-01-14 18:41

2015年1月14日讯 /生物谷BIOON/ --随着医药研究的深入,人们越来越意识到药物的靶向性在疾病治疗中所起的重要作用。因此,具有良好靶向性的抗体药物也收到了药物研发者前所未有的重视。

抗体能够特异性、单一性的识别抗原已经成为许多人的共识。但是,对于一些疾病如肿瘤来说,单特异性的抗体可能无法很好的完成这一治疗任务。而有鉴于此,著名的生物技术公司Adimab公司将自己的研究重心放在了寻找双特异性抗体领域并建立起了独一无二的平台。

研究人员首先分离两种不同的单克隆抗体,纯化后再将这两种抗体以一定方式偶联起来,这样就合成了一种具有不同靶向性的双特异性抗体。这一技术在治疗一些复杂疾病上有着广阔的前景。

最近Adimab宣布与制药巨头葛兰素史克公司达成协议,共同开发双特异性抗体。协议规定,Adimab公司将利用公司独有的抗体技术为葛兰素史克公司建立一个抗体库,供其进行多靶点抗体的筛选。而葛兰素史克公司也成为了第一家和Adimab公司达成类似服务协议的公司。负责葛兰素史克公司生物医药研发的Neil Brewis也表现出了对这一协议的期待:Adimab公司的双特异性抗体技术能够为葛兰素史克公司快速筛选出稳定的双特异性抗体,这一技术将有助于葛兰素史克公司未来在这一领域中更好的筛选合适的药物分子。

而Adimab公司也并不是浪得虚名,公司开发的人类全长抗体研发和搜索技术平台能够以前所未有的速度来合成、纯化人类全长抗体。目前公司的主要业务范围是为各个生物医药公司提供相应的抗体筛选服务。其合作伙伴包括了默沙东、罗氏、礼来在内的20多家生物医药公司。(生物谷Bioon.com)

详细英文报道:

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a technology leader in the discovery of fully human antibodies and bispecifics, today announced that GlaxoSmithKline (GSK) has broadened its relationship with Adimab. Under an expanded collaboration, Adimab will build a unique custom library for GSK for use in generating bispecific antibody leads. Adimab will use that library as well as existing Adimab technology in collaboration with GSK to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets. Adimab will also transfer the novel library to GSK for its internal use in the discovery of bispecifics. GSK will have the right to develop and commercialize therapeutic bispecifics generated from the library. Today's announcement expands on Adimab's first platform technology transfer and license agreement, which was entered into with GSK in 2013.

"We are excited that GSK has decided to be the first company to take advantage of Adimab's unique ability to generate focused antibody libraries for our partners," said Tillman Gerngross, CEO and co-founder of Adimab. "The Adimab platform can identify highly specialized functional IgGs, and incorporate them rapidly into stable, well-expressing bispecific leads. Further, the Adimab platform is a protein engineering tool that allows us to optimize molecules in virtually any bispecific format."

"GSK has an interest in rapidly assessing biology from bispecific molecules with various target combinations, and the Adimab platform fully provides us with the quality and speed we need," said Neil Brewis, Head of Biopharmaceutical Research at GSK. "Our existing collaboration has been highly productive, and this expansion reflects our appreciation of Adimab's capabilities and collaborative approach."

Over the past five years, Adimab has established funded discovery collaborations with more than 25 companies. Adimab's funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin and Celgene. Adimab has strategically partnered with many other companies as well, including Merrimack, Five Prime, Jounce, Innovent, Alector and Arsanis. In addition, Adimab has transferred its platform for broad use to GSK, Biogen Idec and Novo Nordisk.

About Adimab

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human lgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies and bispecifics that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad array of technology access arrangements.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库